Researchers say they have developed a blood test that can help predict the start of Alzheimer's disease symptoms, allowing them to receive a diagnosis.

Oral semaglutide (a GLP-1 pill) is not effective at slowing progression in patients with mild Alzheimer's disease, finds the ...

A team linked to Duke University and the UNC Alzheimer’s Disease Research Center has found that a simple brush swab of the nasal lining can pick up molecular and immune cell changes tied to ...

Research from UC Santa Cruz indicates that the P3 peptide—an alternative cleavage product of the amyloid precursor protein—may play a role in Alzheimer’s disease.

In the brain, Alzheimer’s is characterized by two proteins, amyloid beta and tau, that become dysfunctional, forming plaques ...

New findings suggest that targeting inflammation in Alzheimer’s may matter as much as targeting protein buildup.

Biomed Industries, Inc. Presented Breakthrough Unified Theory Linking Alzheimer’s Disease, Obesity and Cardiovascular ...

GLP-1 receptor agonist indications continue to expand beyond glycaemic and weight control, with benefits now shown in chronic kidney disease in type 2 diabetes, obesity-related heart failure, knee ...

A powerful new real-world data platform could transform how scientists predict and understand Alzheimer’s disease and Alzheimer’s disease related dementias (AD/ADRD), reports a new study at Columbia ...

Amyloid beta and tau proteins compete for the same binding sites on microtubules in neurons, suggesting that displacement of ...

Some people with the gene did not have expected outcomes if they were heavy meat-eaters ...

POTOMAC, MD / ACCESS Newswire / March 18, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics for Alzheimer's disease, ...